Investigational research framing

Stage III — locally advanced / regional node involvement

Stage III typically means disease that is locally advanced and/or involves regional lymph nodes — still without distant metastasis in classic solid-tumour staging. Exact criteria vary by cancer type (breast, colorectal, lung, head and neck, etc.). Always use your TNM report and tumour board plan.

Not medical advice — not a DIY dose protocol More advanced disease means more need for coordinated oncology care — not less. Ivermectin (IVM), fenbendazole (FBZ) and mebendazole (MBZ) appear here only as investigational research interest. They must never replace standard of care (SOC).

1. What stage III usually implies

Locally advanced primary and/or regional nodal involvement (definitions are disease-specific).
Treatment is often multimodal: surgery, radiotherapy (RT), chemotherapy, immunotherapy, targeted therapy — sequenced by the oncology team.
Restaging, pathologic nodal status and molecular markers frequently change the plan after neoadjuvant therapy.
Stage III is not “one protocol”; it is a family of high-complexity pathways.

2. Standard of care is primary

For stage III, evidence-based multimodal SOC is the backbone of survival and local control data. Decisions (neoadjuvant vs upfront surgery, RT fields, ICI eligibility, adjuvant duration) belong with the treating oncologist and multidisciplinary board.

Do not trade proven care for internet protocols Delaying indicated surgery, chemoradiation or immunotherapy to self-administer antiparasitics is not supported by this site and can be harmful.

3. Investigational IVM / FBZ / MBZ — adjunct research interest only

Patients and some clinicians follow drug-repurposing literature because stage III care already involves combinations. Formal evidence for antiparasitic agents as cancer drugs remains early, heterogeneous and mostly outside a clean “stage III solid tumour” label.

Never replace SOC with IVM, FBZ or MBZ monotherapy or informal cocktails.
Combination trials are the ethical place where investigational agents may appear alongside chemo or ICI.
Observational / real-world reports can generate hypotheses; they do not define stage III standards.

4. Research contexts often cited (with limits)

B Johns Hopkins — MBZ phase I, newly diagnosed high-grade glioma + TMZ

Gallia et al. 2021 · NCT01729260 — dose escalation with temozolomide; safety/tolerability focus; median OS reported as exploratory signal, not a stage-III solid-tumour template.

PMC NCT01729260
A Patil 2022 — phase II recurrent glioblastoma

Different setting (recurrent HGG, not classic solid-tumour stage III). Both arms included MBZ; study missed its internal 9-month OS target — include this limitation when discussing MBZ.

DOI PubMed
A Egypt — MBZ combination in metastatic colorectal cancer

Hegazy et al. / NCT03925662 — small single-centre RCT: MBZ + FOLFOX/bevacizumab. Metastatic (not stage III) setting; positive signal needs independent replication.

NCT03925662
R IVM + immune checkpoint inhibitors

NCT05318469 (metastatic TNBC + ICI; ASCO interim activity noted in public abstracts) and NCT07487805 ICONIC (solid tumours + ICI). Advanced/metastatic trial designs — check live registry status.

NCT05318469 NCT07487805 ASCO abstract
B Real-world IVM + MBZ observational cohorts

e.g. Hulscher et al. 2026 — mixed cancers, self-reported outcomes and tolerability. Not randomised stage-III efficacy evidence; selection and reporting bias apply.

PubMed
D/C Fenbendazole

Stronger preclinical/case-series footprint than formal oncology RCTs. Veterinary product; no approved human cancer dose. See FBZ page.

5. Why stage III needs tighter coordination

Locally advanced disease often means longer multimodal sequences, higher cumulative toxicity risk, and more concurrent drugs. Adding unmonitored agents raises interaction, liver, marrow and absorption issues — especially with chemo-RT or ICI. That is why investigational interest, if any, should go through the care team or a registered trial — not a private schedule from social media.

6. Process: oncologist questions, trial search, labs

Confirm stage language — clinical vs pathologic stage III; N category; response after neoadjuvant therapy.
Write the SOC map — surgery / RT / chemo / ICI / targeted start and stop dates; restaging milestones.
Ask structured questions
- Are there open trials for my tumour type and stage (including repurposing or ICI combinations)?
- If I read about IVM/MBZ/FBZ, which interactions matter with my regimen?
- Which labs (ALT/AST, CBC, renal, ECG if relevant) would be required under any experimental plan?
- Who on the team handles complementary/experimental questions?
Search registries — ClinicalTrials.gov (condition + stage + country); also national registries and your hospital trial list.
Document everything — pharmacy review of all OTC, veterinary and online products before concurrent use.

7. Published dose ranges (facts with links — not medical orders)

The following ranges appear in published protocols or reports. They document research practice under monitoring. They are not instructions to self-dose for stage III cancer.

Context	Published dose fact	Original
MBZ phase I + TMZ (newly diagnosed HGG)	Escalation ~25–200 mg/kg/day; reversible grade 3 ALT/AST at high end in some patients	Gallia 2021 · NCT01729260
MBZ case, metastatic ACC (Michigan)	100 mg twice daily monotherapy (case report)	PubMed 21454232
MBZ + FOLFOX/bev (mCRC RCT arm)	500 mg twice daily in experimental arm	NCT03925662
Patil 2022 recurrent GBM	MBZ with lomustine or temozolomide per trial protocol (both arms MBZ)	DOI
IVM + ICI trials	Doses defined in NCT protocols; verify current documents on ClinicalTrials.gov	NCT05318469 · NCT07487805

No DIY medical orders Copying a trial milligram figure into a home regimen without eligibility review, monitoring and consent is unsafe and is not endorsed here. FBZ in particular has no approved human oncology dose.

8. Bottom line for stage III

Stage III ≈ locally advanced / regional nodes (varies by cancer) → high need for coordinated multimodal SOC.
IVM / FBZ / MBZ = investigational adjunct research interest only; never a substitute for oncology care.
Prefer registered combination trials over unsupervised self-treatment.
Use published dose ranges as literature facts with links — not prescriptions.
Bring questions, trial search results and full medication lists to the oncologist.

Protocols hub ← Stage II Studies Mebendazole Ivermectin

4. Example regimens found in literature / public protocols

Below are cited examples (trials, cases, patient protocols) — not a prescription for you. In stage I: keep multimodal SOC primary.

Example	Type	Published / discussed regimen	Source
MBZ — Michigan ACC	Case	Mebendazole 100 mg twice daily monotherapy after other therapy stopped; ~19 mo stability in the case	PubMed 21454232
MBZ — Gallia / Hopkins HGG	Phase I	Mebendazole oral dose escalation ~25–200 mg/kg/day with temozolomide; LFTs monitored	NCT01729260
MBZ — Egypt mCRC	Small RCT arm	Mebendazole 500 mg twice daily + FOLFOX4/bevacizumab	NCT03925662
IVM — Cedars-Sinai TNBC	Phase I/II	Ivermectin oral 30 / 45 / 60 mg on days 1–3, 8–10, 15–17 of each 21-day cycle + ICI	NCT05318469
IVM — ICONIC	Phase II	~200 vs 400 µg/kg ivermectin + checkpoint inhibitor	NCT07487805
FBZ — Tippens-style	Community	Fenbendazole often ~222 mg/day in cyclic schedules + supplements; often concurrent with other cancer therapy	ACS
FBZ — veterinary label	Animal label	Panacur C typically 50 mg/kg × 3 days for GI worms — not a human cancer indication	DailyMed

Stage III reading of the table Most published human doses come from advanced disease or specialized trials — not from intensive multimodal stage III pathways. Map of what existed in protocols, not what you “should take” after surgery.